Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of TAS-119 in Patients With Advanced Solid Tumors

Trial Profile

A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of TAS-119 in Patients With Advanced Solid Tumors

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 14 Oct 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TAS 119 (Primary)
  • Indications Adenocarcinoma; Adrenocortical carcinoma; Advanced breast cancer; Chondrosarcoma; Colorectal cancer; Endocrine gland neoplasms; Endometrial cancer; Gastric cancer; Head and neck cancer; Lung cancer; Mesothelioma; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cancer; Small cell lung cancer; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 06 Oct 2020 Results published in the British Journal of Cancer
    • 18 Feb 2020 Status changed from active, no longer recruiting to discontinued.
    • 04 Jun 2019 Results assessing safety and tolerability of TAS-119 in patients with advanced solid tumors, presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top